Mary Ann Liebert: Gene Therapy to Treat Chronic Hypereosinophilia
January 07, 2025
January 07, 2025
NEW ROCHELLE, New York, Jan. 7 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody (mAb) directed against human eosinophils. The heavy and light chains of that fully human anti-human eosinophil mAb were delivered via an adeno-associated virus (AAV)-based gene therapy to immunodeficient mice, where they suppressed levels of human eosinophils in . . .
A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody (mAb) directed against human eosinophils. The heavy and light chains of that fully human anti-human eosinophil mAb were delivered via an adeno-associated virus (AAV)-based gene therapy to immunodeficient mice, where they suppressed levels of human eosinophils in . . .